Pharvaris N.V. $PHVS Shares Sold by Eversept Partners LP

Eversept Partners LP reduced its stake in Pharvaris N.V. (NASDAQ:PHVS) by 7.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 406,960 shares of the company’s stock after selling 32,217 shares during the period. Eversept Partners LP’s holdings in Pharvaris were worth $11,497,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new position in shares of Pharvaris in the 3rd quarter valued at $1,943,000. PSP Research LLC acquired a new stake in Pharvaris during the 4th quarter worth $569,000. JPMorgan Chase & Co. raised its stake in Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after acquiring an additional 23,743 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in Pharvaris in the fourth quarter valued at $1,536,000. Finally, Commodore Capital LP lifted its position in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the last quarter.

Insider Activity

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the sale, the insider directly owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. This trade represents a 24.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elisabeth Bjork sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total value of $293,200.00. Following the sale, the director directly owned 15,167 shares of the company’s stock, valued at $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 274,555 shares of company stock valued at $8,880,601.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $33.97 on Tuesday. Pharvaris N.V. has a 1 year low of $19.12 and a 1 year high of $36.60. The company has a market capitalization of $2.22 billion, a P/E ratio of -10.68 and a beta of -2.34. The company’s fifty day moving average is $32.56 and its two-hundred day moving average is $29.34.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts expect that Pharvaris N.V. will post -2.97 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on PHVS. Wells Fargo & Company started coverage on Pharvaris in a report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price objective on the stock. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Citizens Jmp dropped their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Wolfe Research initiated coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and a consensus target price of $50.08.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.